Bavarian Nordic (CPSE:BAVA) Names New CEO On A Narrative That Still Looks Undervalued

Bavarian Nordic (CPSE:BAVA) put leadership in the spotlight after naming Tarja Stenvall as President and CEO, effective 15 October 2026. Investors now have a clear focal point for assessing the company’s next phase.

Bavarian Nordic’s recent leadership change comes at a time when momentum in the share price has been building. The 30-day share price return is 9.74% and the 90-day gain is 18.18%, even as the 1-year total shareholder return has declined 9.98%.

Scan how investors are positioning around Bavarian Nordic’s leadership reset and compare it with a hand picked 618 high quality undiscovered gems that may be flying under most radars.

The share price has bounced, yet Bavarian Nordic still trades at a sizeable discount to both analyst targets and estimated fair value. Is the market rightly cautious after recent setbacks, or is it mispricing the leadership reset?

Most Popular Narrative: 24% Undervalued

Bavarian Nordic last closed at DKK207.40, while the most followed narrative anchors fair value at DKK273.33. The valuation gap it highlights is already visible in the price screen.

The company's recent revenue surge and margin strength are heavily anchored in exceptional short-term demand for travel health and public preparedness vaccines. This may be unsustainable as contract wins and outbreak-based orders normalize. This could lead to a flattening or decline in revenues and/or increased volatility in future earnings as pandemic and epidemic fears subside.

See why 33 investors see Bavarian Nordic as 24% undervalued.

The narrative uses a 5.39% discount rate and ties its DKK273.33 fair value to forecasts of broadly flat revenue, contracting profit margins around 16.1%, and earnings of DKK987.7m by 2029 that reflect lower expectations than today, while still assigning value to Bavarian Nordic’s vaccine portfolio and public preparedness contracts.

Result: Fair Value of DKK273.33 (UNDERVALUED)

Still, Bavarian Nordic’s concentrated vaccine portfolio and reliance on government stockpiling could quickly challenge that undervaluation story if pricing or contract momentum weakens.

Find out about the key risks to this Bavarian Nordic narrative.

Next Steps

Sentiment around Bavarian Nordic is split, with clear concerns and real upside arguments sitting side by side. Move quickly, review the data, and weigh both the 4 key rewards and 3 important warning signs.

Looking for more Bavarian Nordic sized ideas?

If Bavarian Nordic has sharpened your focus on where capital works hardest, do not stop here. Broader opportunities sit just a few clicks away.

• Target steady compounding by scanning a curated pool of income opportunities through 158 dividend fortresses that aim to keep cash flowing into your account.
• Hunt for quality at a discount by filtering companies with strong fundamentals using the 173 high quality undervalued stocks that may offer more value than their current prices suggest.
• Prioritise resilience by reviewing a 105 resilient stocks with low risk scores designed to surface businesses with sturdier financial profiles when conditions get tougher.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com